Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine.

PubWeight™: 4.73‹?› | Rank: Top 1%

🔗 View Article (PMC 2753130)

Published in J Virol on August 05, 2009


Urvi M Parikh1, Charles Dobard, Sunita Sharma, Mian-er Cong, Hongwei Jia, Amy Martin, Chou-Pong Pau, Debra L Hanson, Patricia Guenthner, James Smith, Ellen Kersh, J Gerardo Garcia-Lerma, Francis J Novembre, Ron Otten, Thomas Folks, Walid Heneine

Author Affiliations

1: Laboratory Branch, Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.

Articles citing this

(truncated to the top 100)

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science (2010) 35.19

Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med (2015) 9.20

HIV prevention transformed: the new prevention research agenda. Lancet (2011) 4.23

In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS One (2010) 4.08

Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention. PLoS One (2011) 3.27

Microbicides & their implications in HIV prevention. Indian J Med Res (2010) 2.36

Preexposure prophylaxis for HIV prevention: where have we been and where are we going? J Acquir Immune Defic Syndr (2013) 2.13

A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel. PLoS One (2011) 2.06

Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial. Lancet Infect Dis (2014) 2.05

A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel. PLoS One (2011) 2.00

Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence. Curr Opin Infect Dis (2012) 1.97

One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates. J Virol (2011) 1.77

Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue. J Virol (2011) 1.56

Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges. Proc Natl Acad Sci U S A (2013) 1.50

Humanized mouse models of HIV infection. AIDS Rev (2011) 1.49

Use of antiretrovirals for HIV prevention: what do we know and what don't we know? Curr HIV/AIDS Rep (2013) 1.49

Pharmacokinetics of tenofovir following intravaginal and intrarectal administration of tenofovir gel to rhesus macaques. Antimicrob Agents Chemother (2011) 1.48

Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen. PLoS One (2012) 1.42

Targeting Trojan Horse leukocytes for HIV prevention. AIDS (2010) 1.40

Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring. Antimicrob Agents Chemother (2011) 1.38

Systemic and topical drugs for the prevention of HIV infection: antiretroviral pre-exposure prophylaxis. Annu Rev Med (2012) 1.36

An antiretroviral/zinc combination gel provides 24 hours of complete protection against vaginal SHIV infection in macaques. PLoS One (2011) 1.35

Microbicides: topical prevention against HIV. Cold Spring Harb Perspect Med (2012) 1.31

Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. J Control Release (2010) 1.28

Antiretroviral therapy as HIV prevention: status and prospects. Am J Public Health (2010) 1.25

Rapid dissemination of SIV follows multisite entry after rectal inoculation. PLoS One (2011) 1.24

Preexposure prophylaxis for HIV prevention. Curr HIV/AIDS Rep (2011) 1.24

An intravaginal ring that releases the NNRTI MIV-150 reduces SHIV transmission in macaques. Sci Transl Med (2012) 1.23

Pharmacologic opportunities for HIV prevention. Clin Pharmacol Ther (2010) 1.19

Animal models for microbicide studies. Curr HIV Res (2012) 1.17

A single dose of a MIV-150/Zinc acetate gel provides 24 h of protection against vaginal simian human immunodeficiency virus reverse transcriptase infection, with more limited protection rectally 8-24 h after gel use. AIDS Res Hum Retroviruses (2012) 1.16

Preventing mucosal HIV transmission with topical microbicides: challenges and opportunities. Antiviral Res (2010) 1.15

Mucosal HIV-1 transmission and prevention strategies in BLT humanized mice. Trends Microbiol (2012) 1.15

Oral antiretroviral chemoprophylaxis: current status. Curr Opin HIV AIDS (2012) 1.13

Safety and pharmacokinetics of intravaginal rings delivering tenofovir in pig-tailed macaques. Antimicrob Agents Chemother (2012) 1.11

The future role of rectal and vaginal microbicides to prevent HIV infection in heterosexual populations: implications for product development and prevention. Sex Transm Infect (2011) 1.10

Safe and sustained vaginal delivery of pyrimidinedione HIV-1 inhibitors from polyurethane intravaginal rings. Antimicrob Agents Chemother (2011) 1.10

Increased susceptibility to vaginal simian/human immunodeficiency virus transmission in pig-tailed macaques coinfected with Chlamydia trachomatis and Trichomonas vaginalis. J Infect Dis (2014) 1.09

Bridging the gap between preclinical and clinical microbicide trials: blind evaluation of candidate gels in murine models of efficacy and safety. PLoS One (2011) 1.08

The nonnucleoside reverse transcriptase inhibitor MIV-150 in carrageenan gel prevents rectal transmission of simian/human immunodeficiency virus infection in macaques. J Virol (2011) 1.07

The nonnucleoside reverse transcription inhibitor MIV-160 delivered from an intravaginal ring, but not from a carrageenan gel, protects against simian/human immunodeficiency virus-RT Infection. AIDS Res Hum Retroviruses (2012) 1.04

Development of a pigtail macaque model of sexually transmitted infection/HIV coinfection using Chlamydia trachomatis, Trichomonas vaginalis, and SHIV(SF162P3). J Med Primatol (2011) 1.03

The Promise of Antiretrovirals for HIV Prevention. Curr Infect Dis Rep (2012) 1.02

Antiretroviral-based HIV-1 prevention: antiretroviral treatment and pre-exposure prophylaxis. Antivir Ther (2012) 1.02

Formulation, pharmacokinetics and pharmacodynamics of topical microbicides. Best Pract Res Clin Obstet Gynaecol (2012) 1.01

Advances in the Development of Microbicides for the Prevention of HIV Infection. Curr Infect Dis Rep (2010) 0.99

Pharmacokinetics and pharmacodynamics in HIV prevention; current status and future directions: a summary of the DAIDS and BMGF sponsored think tank on pharmacokinetics (PK)/pharmacodynamics (PD) in HIV prevention. AIDS Res Hum Retroviruses (2013) 0.98

Formulation of tenofovir-loaded functionalized solid lipid nanoparticles intended for HIV prevention. J Pharm Sci (2011) 0.98

Animal models for microbicide safety and efficacy testing. Curr Opin HIV AIDS (2013) 0.94

Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness. J Acquir Immune Defic Syndr (2015) 0.93

T cell chemo-vaccination effects after repeated mucosal SHIV exposures and oral pre-exposure prophylaxis. PLoS One (2011) 0.93

Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model. Antimicrob Agents Chemother (2014) 0.93

pH-responsive nanoparticles releasing tenofovir intended for the prevention of HIV transmission. Eur J Pharm Biopharm (2011) 0.90

Pharmacokinetic and safety analyses of tenofovir and tenofovir-emtricitabine vaginal tablets in pigtailed macaques. Antimicrob Agents Chemother (2014) 0.89

4040 SNPs for genomic analysis in the rhesus macaque (Macaca mulatta). Genomics (2011) 0.88

Analysis of repeated low-dose challenge studies. Stat Med (2015) 0.87

SHIV-162P3 infection of rhesus macaques given maraviroc gel vaginally does not involve resistant viruses. PLoS One (2011) 0.87

HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model. Virology (2014) 0.87

Preclinical evaluation of the HIV-1 fusion inhibitor L'644 as a potential candidate microbicide. Antimicrob Agents Chemother (2012) 0.86

Topical prophylaxis for HIV prevention in women: becoming a reality. Curr HIV/AIDS Rep (2011) 0.86

Global expression of molecular transporters in the human vaginal tract: implications for HIV chemoprophylaxis. PLoS One (2013) 0.85

Non-specific microbicide product development: then and now. Curr HIV Res (2012) 0.85

Stimulus-responsive hydrogels: Theory, modern advances, and applications. Mater Sci Eng R Rep (2015) 0.83

A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection. Expert Opin Investig Drugs (2012) 0.82

Increased Dapivirine tissue accumulation through vaginal film codelivery of dapivirine and Tenofovir. Mol Pharm (2014) 0.81

Characterization of UC781-tenofovir combination gel products for HIV-1 infection prevention in an ex vivo ectocervical model. Antimicrob Agents Chemother (2012) 0.81

Potential role of tenofovir vaginal gel for reduction of risk of herpes simplex virus in females. Int J Womens Health (2012) 0.81

Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis. PLoS One (2013) 0.81

Susceptibility to repeated, low-dose, rectal SHIVSF162P3 challenge is independent of TRIM5 genotype in rhesus macaques. AIDS Res Hum Retroviruses (2013) 0.81

Clinical Treatment Options Infectious Diseases: Update on PrEP Implementation, Adherence, and Advances in Delivery. Curr Treat Options Infect Dis (2015) 0.81

Short communication: a repeated simian human immunodeficiency virus reverse transcriptase/herpes simplex virus type 2 cochallenge macaque model for the evaluation of microbicides. AIDS Res Hum Retroviruses (2014) 0.80

Repeated Vaginal SHIV Challenges in Macaques Receiving Oral or Topical Preexposure Prophylaxis Induce Virus-Specific T-Cell Responses. J Acquir Immune Defic Syndr (2015) 0.80

Evaluation of the lymphocyte trafficking drug FTY720 in vaginal tissues. J Med Primatol (2013) 0.80

In search of the optimal delivery method for anti-HIV microbicides: are intravaginal rings the way forward? Expert Rev Anti Infect Ther (2013) 0.80

Evaluation of Rapidly Disintegrating Vaginal Tablets of Tenofovir, Emtricitabine and Their Combination for HIV-1 Prevention. Pharmaceutics (2014) 0.80

Efficacy of Tenofovir 1% Vaginal Gel in Reducing the Risk of HIV-1 and HSV-2 Infection. Clin Med Insights Womens Health (2014) 0.79

Relationship of Estimated SHIV Acquisition Time Points During the Menstrual Cycle and Thinning of Vaginal Epithelial Layers in Pigtail Macaques. Sex Transm Dis (2015) 0.79

Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug delivery. J Control Release (2015) 0.78

Short Communication: Practical Experience with Analysis and Design of Repeat Low-Dose SHIVSF162P3 Exposure Studies in Female Pigtail Macaques with Varying Susceptibility During Menstrual Cycling. AIDS Res Hum Retroviruses (2015) 0.78

The use of preexposure treatments for HIV prophylaxis. HIV AIDS (Auckl) (2012) 0.78

Short communication: Viremic control is independent of repeated low-dose SHIVSF162p3 exposures. AIDS Res Hum Retroviruses (2014) 0.78

Antiretroviral-based HIV prevention strategies for women. Expert Rev Anti Infect Ther (2010) 0.78

Topical Delivery of Tenofovir Disoproxil Fumarate and Emtricitabine from Pod-Intravaginal Rings Protects Macaques from Multiple SHIV Exposures. PLoS One (2016) 0.77

HIV PrEP Trials: The Road to Success. Clin Investig (Lond) (2013) 0.77

Pharmacodynamic correlations using fresh and cryopreserved tissue following use of vaginal rings containing dapivirine and/or maraviroc in a randomized, placebo controlled trial. Medicine (Baltimore) (2016) 0.77

Macaque models of enhanced susceptibility to HIV. Virol J (2015) 0.77

Clinical use of vaginal or rectally applied microbicides in patients suffering from HIV/AIDS. HIV AIDS (Auckl) (2013) 0.77

Rectal application of a highly osmolar personal lubricant in a macaque model induces acute cytotoxicity but does not increase risk of SHIV infection. PLoS One (2015) 0.77

Factors Important to the Prioritization and Development of Successful Topical Microbicides for HIV-1. Mol Biol Int (2012) 0.77

Protection Against Rectal Chimeric Simian/Human Immunodeficiency Virus Transmission in Macaques by Rectal-Specific Gel Formulations of Maraviroc and Tenofovir. J Infect Dis (2015) 0.77

Optimization (central composite design) and validation of HPLC method for investigation of emtricitabine loaded poly(lactic-co-glycolic acid) nanoparticles: in vitro drug release and in vivo pharmacokinetic studies. ScientificWorldJournal (2014) 0.77

Pre-exposure prophylaxis of HIV: A right way to go or a long way to go? Artif Cells Nanomed Biotechnol (2014) 0.77

In vivo binding and retention of CD4-specific DARPin 57.2 in macaques. PLoS One (2010) 0.77

Nondaily preexposure prophylaxis for HIV prevention. Curr Opin HIV AIDS (2016) 0.76

Efficacy of topical tenofovir against transmission of a tenofovir-resistant SHIV in macaques. Retrovirology (2015) 0.76

A Novel Microbicide/Contraceptive Intravaginal Ring Protects Macaque Genital Mucosa against SHIV-RT Infection Ex Vivo. PLoS One (2016) 0.76

A Shot in the Arm for HIV Prevention? Recent Successes and Critical Thresholds. AIDS Res Hum Retroviruses (2015) 0.75

Safety and Pharmacokinetics of Quick-Dissolving Polymeric Vaginal Films Delivering the Antiretroviral IQP-0528 for Preexposure Prophylaxis. Antimicrob Agents Chemother (2016) 0.75

A Macaque Model for Rectal Lymphogranuloma Venereum and Non-Lymphogranuloma Venereum Chlamydia trachomatis: Impact on Rectal Simian/Human Immunodeficiency Virus Acquisition. Sex Transm Dis (2017) 0.75

Prevention of vaginal and rectal HIV transmission by antiretroviral combinations in humanized mice. PLoS One (2017) 0.75

Articles cited by this

New heterosexually transmitted HIV infections in married or cohabiting couples in urban Zambia and Rwanda: an analysis of survey and clinical data. Lancet (2008) 11.20

Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet (2002) 11.02

A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med (1996) 7.60

Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med (2008) 7.46

Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity (2007) 6.36

Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med (1996) 5.63

Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis (2006) 5.24

Semen-derived amyloid fibrils drastically enhance HIV infection. Cell (2007) 5.23

Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med (2009) 4.79

Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature (2005) 4.71

Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J Virol (2005) 4.61

Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS (2006) 4.23

Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. AIDS (2008) 4.21

Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science (1999) 4.09

Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science (2004) 3.95

Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission. J Virol (1996) 3.48

Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3). J Virol (2001) 3.20

Microbicide drug candidates to prevent HIV infection. Lancet (2007) 3.06

The inevitability of infidelity: sexual reputation, social geographies, and marital HIV risk in rural Mexico. Am J Public Health (2007) 3.03

Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLoS One (2007) 2.84

Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. Annu Rev Med (2008) 2.81

Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med (2008) 2.74

The condom is an 'intruder' in marriage: evidence from rural Malawi. Soc Sci Med (2007) 2.68

Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther (2004) 2.45

Violence against wives, sexual risk and sexually transmitted infection among Bangladeshi men. Sex Transm Infect (2007) 2.34

Evaluating the potential impact of vaginal microbicides to reduce the risk of acquiring HIV in female sex workers. AIDS (2005) 2.33

Multiple vaginal exposures to low doses of R5 simian-human immunodeficiency virus: strategy to study HIV preclinical interventions in nonhuman primates. J Infect Dis (2004) 2.29

Whither or wither microbicides? Science (2008) 2.17

The urgent need for a vaginal microbicide in the prevention of HIV transmission. Am J Public Health (1994) 2.03

The political economy of marriage and HIV: the ABC approach, "safe" infidelity, and managing moral risk in Uganda. Am J Public Health (2007) 2.02

Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy. Clin Infect Dis (2008) 1.91

The development of vaginal microbicides for the prevention of HIV transmission. PLoS Med (2005) 1.54

Direct stringency comparison of two macaque models (single-high vs. repeat-low) for mucosal HIV transmission using an identical anti-HIV chemoprophylaxis intervention. J Med Primatol (2007) 1.48

Genital ulcers facilitate rapid viral entry and dissemination following intravaginal inoculation with cell-associated simian immunodeficiency virus SIVmac239. J Virol (2008) 1.36

Men's extramarital sexuality in rural Papua New Guinea. Am J Public Health (2007) 1.34

Repetitive exposures with simian/human immunodeficiency viruses: strategy to study HIV pre-clinical interventions in non-human primates. J Med Primatol (2006) 1.29

Repeated intravaginal inoculation with cell-associated simian immunodeficiency virus results in persistent infection of nonhuman primates. J Infect Dis (2006) 1.20

Effect of mobile phase pH and organic content on LC-MS analysis of nucleoside and nucleotide HIV reverse transcriptase inhibitors. J Chromatogr Sci (2009) 1.16

Characteristics of the menstrual cycle in nonhuman primates. IV. Timed mating in Macaca nemestrina. Lab Anim (1981) 1.10

Development of a nonhuman primate model for Trichomonas vaginalis infection. Sex Transm Dis (2006) 1.08

Women shoulder growing HIV/AIDS burden. JAMA (2005) 1.04

Vaginal myeloperoxidase and flora in the pig-tailed macaque. J Med Primatol (2000) 0.97

Marriage is not a safe place: heterosexual marriage and HIV-related vulnerability in Indonesia. Cult Health Sex (2008) 0.95

HIV's vagina travelogue. Immunity (2007) 0.90

Can a topical microbicide prevent rectal HIV transmission? PLoS Med (2008) 0.84

Articles by these authors

Ensembl's 10th year. Nucleic Acids Res (2009) 10.82

An overview of Ensembl. Genome Res (2004) 10.35

Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One (2009) 8.37

Molecular and functional profiling of memory CD8 T cell differentiation. Cell (2002) 8.06

Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med (2008) 7.71

Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med (2008) 7.46

Quantitative detection of increasing HIV type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and estimating incidence. AIDS Res Hum Retroviruses (2002) 7.03

Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Sci Transl Med (2010) 5.85

A role for Dicer in immune regulation. J Exp Med (2006) 5.81

Naturally acquired simian retrovirus infections in central African hunters. Lancet (2004) 5.34

A physical map of the mouse genome. Nature (2002) 4.97

DNA microarrays for comparative genomic hybridization based on DOP-PCR amplification of BAC and PAC clones. Genes Chromosomes Cancer (2003) 4.68

Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell (2006) 4.13

Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy. PLoS Med (2008) 4.12

The Ensembl Web site: mechanics of a genome browser. Genome Res (2004) 4.10

Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis (2005) 3.91

Absence of evidence of xenotropic murine leukemia virus-related virus infection in persons with chronic fatigue syndrome and healthy controls in the United States. Retrovirology (2010) 3.64

A peer-education intervention to reduce injection risk behaviors for HIV and hepatitis C virus infection in young injection drug users. AIDS (2007) 3.58

Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother (2005) 3.53

Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children. Clin Infect Dis (2009) 3.37

Human cerebral cortex development from pluripotent stem cells to functional excitatory synapses. Nat Neurosci (2012) 3.28

Ensembl variation resources. BMC Genomics (2010) 3.17

TranscriptSNPView: a genome-wide catalog of mouse coding variation. Nat Genet (2006) 3.10

Performance characteristics of the immunoglobulin G-capture BED-enzyme immunoassay, an assay to detect recent human immunodeficiency virus type 1 seroconversion. J Clin Microbiol (2004) 2.94

Determination of mean recency period for estimation of HIV type 1 Incidence with the BED-capture EIA in persons infected with diverse subtypes. AIDS Res Hum Retroviruses (2010) 2.86

Emergence of unique primate T-lymphotropic viruses among central African bushmeat hunters. Proc Natl Acad Sci U S A (2005) 2.86

The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis (2004) 2.76

Ancient co-speciation of simian foamy viruses and primates. Nature (2005) 2.71

Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis (2004) 2.70

Evolutionary and functional analyses of the interaction between the myeloid restriction factor SAMHD1 and the lentiviral Vpx protein. Cell Host Microbe (2012) 2.66

Randomized trial of medical or endoscopic therapy to prevent recurrent ulcer hemorrhage in patients with adherent clots. Gastroenterology (2002) 2.62

Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS (2010) 2.62

Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect Control Hosp Epidemiol (2013) 2.59

Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther (2004) 2.45

Frequent simian foamy virus infection in persons occupationally exposed to nonhuman primates. J Virol (2004) 2.44

Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep (2005) 2.35

HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis. Proc Natl Acad Sci U S A (2010) 2.25

The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions. J Virol (2006) 2.10

Simple PCR assays improve the sensitivity of HIV-1 subtype B drug resistance testing and allow linking of resistance mutations. PLoS One (2007) 2.09

c-kit expression identifies cardiovascular precursors in the neonatal heart. Proc Natl Acad Sci U S A (2009) 2.06

Serologic evidence for exposure to simian virus 40 in North American zoo workers. J Infect Dis (2004) 1.98

Ezh2, the histone methyltransferase of PRC2, regulates the balance between self-renewal and differentiation in the cerebral cortex. Proc Natl Acad Sci U S A (2010) 1.97

A human stem cell model of early Alzheimer's disease pathology in Down syndrome. Sci Transl Med (2012) 1.95

Mechano-coupling and regulation of contractility by the vinculin tail domain. Biophys J (2007) 1.92

The level of the transcription factor Pax6 is essential for controlling the balance between neural stem cell self-renewal and neurogenesis. PLoS Genet (2009) 1.92

Mutagenic insertion and chromosome engineering resource (MICER). Nat Genet (2004) 1.88

Comparison of accuracy and safety of the SEVEN and the Navigator continuous glucose monitoring systems. Diabetes Technol Ther (2009) 1.88

Evaluation of dried blood spots for human immunodeficiency virus type 1 drug resistance testing. J Clin Microbiol (2006) 1.83

HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges. Virology (2006) 1.83

Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis (2003) 1.80

Requirement for integrase during reverse transcription of human immunodeficiency virus type 1 and the effect of cysteine mutations of integrase on its interactions with reverse transcriptase. J Virol (2004) 1.79

High susceptibility to repeated, low-dose, vaginal SHIV exposure late in the luteal phase of the menstrual cycle of pigtail macaques. J Acquir Immune Defic Syndr (2011) 1.74

A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation. J Virol (2003) 1.63

Genome3D: a UK collaborative project to annotate genomic sequences with predicted 3D structures based on SCOP and CATH domains. Nucleic Acids Res (2012) 1.63

High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients. AIDS (2007) 1.62

Developing a scholarship community. J Nurs Scholarsh (2005) 1.61

Nef-mediated enhancement of virion infectivity and stimulation of viral replication are fundamental properties of primate lentiviruses. J Virol (2007) 1.58

Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue. J Virol (2011) 1.56

Failure to confirm XMRV/MLVs in the blood of patients with chronic fatigue syndrome: a multi-laboratory study. Science (2011) 1.56

Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges. Proc Natl Acad Sci U S A (2013) 1.50

Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire. AIDS (2003) 1.50

Methods to recruit and retain a cohort of young-adult injection drug users for the Third Collaborative Injection Drug Users Study/Drug Users Intervention Trial (CIDUS III/DUIT). Drug Alcohol Depend (2007) 1.50

Antithymocyte globulin and cyclosporin in children with acquired aplastic anemia. Indian J Pediatr (2008) 1.49

Oral pre-exposure prophylaxis for HIV prevention. Trends Pharmacol Sci (2009) 1.48

Long-lived poxvirus immunity, robust CD4 help, and better persistence of CD4 than CD8 T cells. J Virol (2004) 1.46

SHIV-1157i and passaged progeny viruses encoding R5 HIV-1 clade C env cause AIDS in rhesus monkeys. Retrovirology (2008) 1.45

Detection of human immunodeficiency virus type 1 DNA in dried blood spots by a duplex real-time PCR assay. J Clin Microbiol (2005) 1.44

Screening for simian foamy virus infection by using a combined antigen Western blot assay: evidence for a wide distribution among Old World primates and identification of four new divergent viruses. Virology (2003) 1.44

Trends in perimortal conditions and mortality rates among HIV-infected patients. AIDS (2007) 1.43

When to begin highly active antiretroviral therapy? Evidence supporting initiation of therapy at CD4+ lymphocyte counts <350 cells/microL. Clin Infect Dis (2003) 1.42

Complex haplotypes, copy number polymorphisms and coding variation in two recently divergent mouse strains. Nat Genet (2005) 1.42

Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen. PLoS One (2012) 1.42

Serologic and PCR testing of persons with chronic fatigue syndrome in the United States shows no association with xenotropic or polytropic murine leukemia virus-related viruses. Retrovirology (2011) 1.42

Few smokers in South Auckland access subsidised nicotine replacement therapy. N Z Med J (2010) 1.41

Trends in pregnancy rates among women with human immunodeficiency virus. Obstet Gynecol (2004) 1.40

Essential thrombocytosis and antiphospholipid antibody syndrome causing chronic Budd-Chiari syndrome. Indian J Pediatr (2011) 1.39

Differences in prescription of antiretroviral therapy in a large cohort of HIV-infected patients. J Acquir Immune Defic Syndr (2003) 1.39

Can the prevalence of diagnosed diabetes be estimated from linked national health records? The validity of a method applied in New Zealand. J Prim Health Care (2011) 1.39

A mother and daughter with a novel phenotype of hand and foot abnormalities and severe pectus excavatum. Am J Med Genet A (2013) 1.38

Hemoglobin Agenogi - A rare abnormal beta globin chain variant. Indian J Pathol Microbiol (2016) 1.38

Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors. J Virol (2011) 1.38